CoChat
Sign Up
Cited by 2,967

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Druker, Brian J., Tamura, Shu, Buchdunger, Elisabeth, Ohno, Sayuri, Segal, Gerald M., Fanning, Shane, Zimmermann, Jürg, Lydon, Nicholas B.·1996·Nature Medicine
DOI 10.1038/nm0596-561
Open this paper in CoChat — free account

Abstract

The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

Overview

Integrity signals

Registry

Crossref · 10.1038/nm0596-561

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 51

  1. Kantarjian, H.M., Deisseroth, A.B., Kurzrock, R., Estrov, Z., & Talpaz, M., Chronic myelogenous leukemia: A concise update. Blood 82, 691–703 (1993). · DOI
  2. Allan, N.C., Shepard, P.C.A. & Richards, R.M. Interferon alpha prolongs survival for patients with CML in chronic phase: Preliminary results of the UK MRC randomized multicenter trial. Blood 84, 382a (1994).
  3. The Italian Cooperaticellve Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820–825 (1994). · DOI
  4. Ozer, H., et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood. 82, 2975–2984 (1993). · DOI
  5. O'Brien, S.G. & Goldman, J.M. Autografting in chronic myeloid leukaemia. Blood Rev. 8, 63–69 (1994). · DOI
  6. McGlave, P.B., et al. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343, 1486–1488 (1994). · DOI
  7. O'Brien, S.G. & Goldman, J.M. Current approaches to hematopoietic stem-Cell purging in chronic myeloid leukemia. J. Clin. Oncol. 13, 541–546 (1995). · DOI
  8. Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1501 (1960).
  9. Heisterkamp, N., et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature. 306, 239–242 (1983). · DOI
  10. Bartram, C.R. et al. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 306, 277–280 (1983). · DOI
  11. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315, 550–554 (1985). · DOI
  12. Clark, S.S., et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 239, 775–777 (1988). · DOI
  13. Scott, M.L., Van Etten, R., Daley, G.Q. & Baltimore, D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc. Natl. Acad. Sci. USA. 88, 6506–6510 (1991). · DOI
  14. Kelliher, M.A., McLaughlin, J., Witte, O.N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA. 87, 6649–6653 (1990). · DOI
  15. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247, 824–830 (1990). · DOI · Paper page
  16. Oda, T., Tamura, S., Matsuguchi, T., Griffin, J.D. & Druker, B.J. The SH2 domain of Abl is not required for factor independent growth induced by Bcr-Abl in a murine myeloid Cell line. Leukemia. 9, 295–301 (1995).
  17. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247, 1079–1082 (1990). · DOI
  18. Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933–935 (1988). · DOI
  19. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science. 267, 1782–1788 (1995). · DOI
  20. Kaur, G., et al. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs. 5, 213–222 (1994). · DOI
  21. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y. & Levitzki, A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood. 82, 3524–3529 (1993). · DOI
  22. Furet, P., et al. Modeling study of protein kinase inhibitors – binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput. Aided Mol. Des. 9, 465–472 (1995). · DOI
  23. Laneuville, P., Heisterkamp, N. & Groffen, J. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid Cell line. Oncogene 6, 275–282 (1991).
  24. Matulonis, U., Salgia, R., Okuda, K., Druker, B. & Griffin, J.D. IL-3 and p210BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid Cell line. Exp. Hematol. 21, 1460–1466 (1993).
  25. Daley, G.Q. & Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic Cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA. 85, 9312–9316 (1988). · DOI
  26. Honma, Y., Okabe, K.J., Hozumi, M., Uehara, Y. & Mizuno, S. Induction of ery-throid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 49, 331–4 (1989).
  27. Schwartzberg, P.L., et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T Cell populations. Cell. 65, 1165–1175 (1991). · DOI
  28. Sawyers, C.L., McLaughlin, J., Goga, A., Havlik, M. & Witte, O. The nuclear tyrosine kinase c-Abl negatively regulates Cell growth. Cell. 77, 121–131 (1994). · DOI
  29. Silvennoinen, O., et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA. 90, 8429–8433 (1993). · DOI
  30. Caracciolo, D., et al. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science. 245, 1107–1110 (1989). · DOI
  31. Martiat, P., et al. Retrovirally transduced antisense sequences stably suppress p210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing Cell lines. Blood. 81, 502–509 (1993). · DOI
  32. Oda, T., et al. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925–22928 (1994). · DOI
  33. Evans, C.A., Owen-Lynch, P.J., Whetton, A.D. & Dive, C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic Cells. Cancer Res. 53, 1735–1738 (1993).
  34. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83, 2038–2044 (1994). · DOI
  35. Heldin, C.H. & Westermark, B. Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul. 1, 555–566 (1990). · DOI
  36. Kanakura, Y., et al. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves a common set of cytoplasmic proteins. Blood. 76, 706–715 (1990). · DOI
  37. Greenberger, J.S., Sakakeeny, M.A., Humphries, R.K., Eaves, C.J., & Eckner, R.J. Demonstration of permanent factor-dependent multipotential (erythroid/neu-trophil/basophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. USA. 80, 2391–2395 (1983). · DOI
  38. Avanzi, G.C., et al. Selective growth response to IL-3 of a human leukaemic Cell line with megakaryoblastic features. Br. J. Haematol. 69, 359–366 (1988). · DOI
  39. Matsuguchi, T., et al. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL. J. Biol. Chem. 269, 5016–5021 (1994). · DOI
  40. Erwin, J.L. & Anderson, S.M. Analysis of phosphotyrosine-containing proteins present in v-src-infected myeloid progenitor cells. Oncogene 7, 1101–1107 (1992).
  41. Mossman, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983). · DOI · Paper page
  42. Orkin, S.H., Harosi, F.I. & Leder, P. Differentiation in erythroleukemia cells and their somatic hybrids. Proc. Natl. Acad. Sci. USA. 72, 98–102 (1975). · DOI
  43. Buchdunger, E., et al. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA. 91, 2334–2338 (1994). · DOI
  44. Buchdunger, E., et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 92, 2558–2562 (1995). · DOI
  45. Arion, D., Meijer, L., Brizuela, L. & Beach, D. cdc2 is a component of the M phase-specific histone HI kinase: Evidence for identity with MPF. Cell. 55, 371–378 (1988). · DOI
  46. Pendergast, A.M., et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA. 88, 5927–5931 (1991). · DOI
  47. Kharbanda, S., et al. Activation of the c-abl tyrosine kinase in stress response to DNA-damaging agents. Nature. 376, 785–788 (1995). · DOI
  48. Evans, B.D., Smith, I.E., Shorthouse, A.J. & Millar, J.L. A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br. J. Cancer. 45, 466–468 (1982). · DOI
  49. Segal, G.M., et al. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor Cells. J. Clin. Invest. 94, 846–852 (1994). · DOI
  50. Hernandez, A., et al. Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction. Exp. Hematol. 18, 1142–1144 (1990).
  51. Dunn, O.J. Multiple comparisons using rank sums. Technometrics 6, 241–252 (1964). · DOI

Cited by

See all 2,967

Metadata

Authors
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
1996-05
Volume
2
Issue
5
Pages
561-566
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/nm0596-561
Cited by
2,967
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. https://app.cochat.ai/papers/10.1038/nm0596-561
The paper
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. https://doi.org/10.1038/nm0596-561